Hepatitis Therapeutics Market By Drug Class (Direct-Acting Antivirals, Nucleos(t)ide Analogues, Immune Modulators, Combination Therapies); By Disease Type (Hepatitis B, Hepatitis C, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Hepatitis Therapeutics Market: Functional-Cure Innovation and Concentrated Country Burden Reshape Antiviral Demand

The Global Hepatitis Therapeutics Market is estimated to reach USD 18.58 billion in 2025 and is projected to grow to USD 29.45 billion by 2032, expanding at a CAGR of 6.8%, driven by antiviral drugs, chronic hepatitis treatment, biologic therapies, direct-acting antivirals, liver disease management, and rising hepatitis prevalence, according to Strategic Market Research.

 

The hepatitis therapeutics market combines three commercially different treatment pathways: recurring viral suppression for chronic hepatitis B, finite curative treatment courses for hepatitis C, and an emerging specialty-drug category for hepatitis D. In 2024, approximately 287 million people were living with chronic HBV or HCV worldwide, including 240 million with HBV and 47 million with HCV. These infections caused an estimated 1.3 million deaths during the year, including approximately 1.1 million associated with HBV and 240,000 associated with HCV.

 

The large epidemiological burden does not convert directly into drug sales. Diagnosis rates remain low, only a fraction of diagnosed HBV patients receive treatment, and HCV demand depends on finding new patients after previous cohorts have been cured. Pricing also differs sharply by country. Public tenders and generic purchasing dominate many high-burden markets, while the United States and parts of Europe support higher-value branded and specialty therapies.

 

The market is therefore better assessed through diagnosed patients, treatment initiations, treated-patient-years, treatment duration, payer access and government procurement than through prevalence alone.

 

A Large Patient Population Produces a Much Smaller Treated Market

HBV represents the largest recurring treatment opportunity, but the commercial patient funnel remains narrow. WHO estimated that only 65 million people, or approximately 27% of the global chronic HBV population, had been diagnosed in 2024. Around 10 million people were receiving antiviral treatment, equal to 4.3% of the chronic population. WHO’s updated guidance indicates that more than half of people with chronic HBV could require treatment, depending on their clinical status and how eligibility criteria are implemented.

Applying the eligibility indication to the 240 million global patient pool produces a theoretical treatment-requiring population exceeding 120 million. This is not an immediately addressable commercial population. Diagnosis, liver-disease assessment, reimbursement, medicine supply and provider capacity determine whether patients progress to treatment.

HCV has a more advanced treatment pathway, although substantial leakage remains. WHO estimates that 47 million people were living with chronic HCV in 2024, with approximately 0.9 million new infections occurring annually. Direct-acting antivirals can cure more than 95% of treated patients in many settings, but treatment demand still depends on active infection confirmation, referral, payment approval and completion of a finite drug course.

 

Ten Countries Control Most of the Addressable Patient Volume

The country ranking shared from The Indian Express is based on WHO’s Global Hepatitis Report 2024 and represents estimated infections in 2022, rather than estimates for 2025. The ten countries collectively accounted for approximately 66% of the combined global HBV and HCV burden in that dataset. WHO separately identifies these same ten markets as carrying nearly two-thirds of the global disease burden.

China ranked first with approximately 79.7 million HBV infections and 4 million HCV infections, producing a combined patient pool of 83.7 million and 27.5% of the global total. Its burden is overwhelmingly HBV-led. China consequently represents the largest potential volume market for oral viral-suppression medicines and one of the most important future launch markets for therapies seeking functional cure. Price negotiation, hospital access, reimbursement and patient identification will determine whether innovative treatments capture significant value beyond established oral antivirals.

India ranked second with 29.8 million HBV infections and 5.5 million HCV infections, or 35.3 million combined cases. India alone represented 11.6% of the global burden reported in the 2022 dataset. Its mixed disease profile creates two separate pharmaceutical opportunities: recurring treatment for chronic HBV and finite DAA courses for HCV. The large patient pool favours manufacturers able to work with public programs, affordable treatment channels, domestic distribution and decentralized testing rather than relying only on private specialist care.

Indonesia had approximately 17.5 million HBV and 1.4 million HCV infections, producing an 18.9 million combined population. Nigeria followed with 14.4 million HBV and 1.35 million HCV infections, or approximately 15.7 million combined cases. Both countries are primarily HBV opportunities, where commercial expansion depends on diagnosis, maternal screening, linkage to long-term antiviral care and government-supported access.

Pakistan presents a different therapeutic profile. Its estimated 8.8 million HCV infections considerably exceeded its 3.8 million HBV infections, producing a combined population of 12.6 million. HCV therefore represents the more immediate pharmaceutical opportunity, particularly for affordable pangenotypic DAA regimens, national screening campaigns and high-volume public procurement. Successful treatment programs can generate large initial course volumes but will eventually reduce the untreated prevalent pool.

Ethiopia had approximately 7.7 million HBV and 692,000 HCV infections, while Bangladesh had 7.2 million HBV and 1.02 million HCV infections. Their combined burdens reached approximately 8.4 million and 8.3 million, respectively. Both markets are HBV-led and require long-term improvements in diagnosis and treatment initiation before their large disease pools translate into recurring pharmaceutical demand.

Viet Nam had an estimated 6.5 million HBV and 900,000 HCV infections, producing a combined burden of 7.4 million. The Philippines had approximately 5.7 million HBV and 400,000 HCV infections, or 6.1 million combined cases. These Southeast Asian markets strengthen the regional commercial importance of HBV suppression and future cure-oriented therapies, although public affordability and treatment infrastructure will remain decisive.

The Russian Federation ranked tenth with approximately 1.7 million HBV and 2.7 million HCV infections, producing a 4.3 million combined population. Unlike most countries in the top-ten list, its burden is more heavily weighted toward HCV. Finite DAA treatment courses therefore represent a larger component of addressable pharmaceutical demand than recurring HBV suppression.

China, India and Indonesia together represented approximately half of the global HBV burden in the 2022 dataset. China, India, Indonesia, Pakistan, Russia and the United States represented approximately half of the HCV burden. Manufacturers cannot treat the ten high-burden markets as a uniform commercial segment: HBV-dominant countries require recurring access models, while HCV-heavy markets depend on screening campaigns and repeated waves of finite treatment initiation.

These 2022 country counts should not be added directly to WHO’s updated 2024 global totals because the estimates reflect different reporting years and modeling cycles.

 

Recurring HBV Suppression Remains the Largest Volume Segment

Established HBV therapeutics are led by oral nucleos(t)ide analogues, particularly tenofovir and entecavir. These medicines suppress viral replication, reduce progression to cirrhosis and liver cancer, and improve long-term outcomes, but they rarely eliminate the infection. Most patients who begin treatment require long-term or lifelong therapy, creating recurring treated-patient-year demand.

This duration gives HBV the strongest recurring revenue structure within the hepatitis therapeutics market. The value per patient is constrained by generic availability, mature treatment standards and the purchasing power of high-burden countries. Suppliers compete through scale, tender participation, manufacturing cost, distribution reach and reliable continuity of supply.

Volume growth will depend on whether diagnosis and treatment programs expand faster than price erosion. WHO’s estimate of 10 million treated patients compared with a 240 million chronic population leaves considerable room for additional prescriptions, but much of that growth is likely to come through price-sensitive public channels rather than premium branded markets.

 

Functional Cure Could Change HBV Treatment Economics

HBV research is moving from indefinite viral suppression toward functional cure, generally involving sustained loss of hepatitis B surface antigen and continued viral control after therapy ends. A successful functional-cure treatment could create a premium finite or sequential treatment segment positioned above inexpensive daily oral medicines.

Bepirovirsen is the most advanced asset in this transition. Phase III studies reported functional cure at week 72 in approximately 19% to 20% of treated patients, compared with no functional cures in the placebo groups. The effect was higher in selected patients with favourable baseline biomarker characteristics, making patient selection commercially important.

The FDA granted bepirovirsen priority review and Breakthrough Therapy Designation in April 2026. The therapy remained investigational as of July 2026. Approval would create a differentiated treatment category, but reimbursement would depend on durability, the eligible biomarker-defined population, administration requirements and whether payers believe the therapy can reduce years of antiviral use and liver-related complications.

Gene-editing and RNA-targeted approaches could eventually compete with both daily suppression and antisense therapies. Their commercial potential is significant because they aim to address persistent viral material, but development risk remains considerably higher than for established oral antivirals. Safety, durability and scalable administration will determine whether these platforms move beyond limited specialist use.

 

HCV Is Curable, but Market Growth Depends on Finding Untreated Patients

Direct-acting antivirals changed HCV from a chronic-management market into a finite-course cure market. Products such as Mavyret, Epclusa and Harvoni can cure most treated patients through oral regimens commonly lasting eight to twelve weeks. Pharmaceutical revenue is therefore tied to treatment starts rather than long-term prescription persistence.

HCV creates a different market challenge from HBV. Every successful cure removes a patient from the prevalent treatment pool, so mature markets can experience declining annual course volume even when access programs perform well. Growth requires new diagnosis, treatment of previously excluded patients, expansion into prisons and harm-reduction settings, reinfection management and removal of payer restrictions.

The United States continues to replenish its treatment pool. CDC reported 4,966 acute HCV cases in 2023, corresponding to an estimated 69,000 infections after adjustment for underdiagnosis and underreporting. The country also recorded 101,525 newly reported chronic cases and 11,194 HCV-related deaths during the year.

Commercial access remains weaker than clinical efficacy. Patients can be diagnosed but fail to start treatment because of prior authorization, insurance disruption, provider shortages or weak linkage between testing and prescribing. These barriers make treatment conversion a more immediate commercial constraint than cure rate in the United States.

Branded HCV products nevertheless retain material value. AbbVie reported USD 1.317 billion in worldwide Mavyret revenue during 2025. Gilead’s wider liver-disease portfolio generated USD 3.2 billion, with higher demand for HBV and HDV products partly offset by lower average realized prices for HCV medicines. These results show a mature category that continues to produce revenue but faces increasing price and patient-pool pressure.

 

Hepatitis D Becomes a Commercial Specialty-Drug Market

HDV is a smaller segment than HBV or HCV, but it has stronger near-term premium potential. Patient identification is difficult because HDV testing is not consistently performed among people with chronic HBV. The commercial population is consequently much smaller than the epidemiological population.

On May 22, 2026, the FDA approved Hepcludex, or bulevirtide-gmod, for adults with chronic HDV who do not have cirrhosis or have compensated cirrhosis. It became the first FDA-approved treatment for chronic HDV and created a new U.S. specialty-pharmaceutical segment. The indication received accelerated approval based on virologic and biochemical outcomes, so confirmatory evidence remains important for long-term positioning.

The HDV commercial pathway requires HBV diagnosis, additional HDV testing, specialist confirmation, payer approval and continuing treatment. Manufacturers must therefore invest in disease education and patient finding rather than relying only on a conventional product launch.

Competition is already developing. Vir Biotechnology’s ECLIPSE program is evaluating tobevibart plus elebsiran in Phase III and comparative studies. One study assesses switching patients who have not achieved viral suppression with bulevirtide, while another directly compares the investigational combination with bulevirtide. The comparative program is designed partly to support future access and reimbursement positioning.

 

Mature and High-Burden Markets Require Different Commercial Models

England demonstrates a mature national HCV procurement and treatment model. Approximately 50,200 adults were estimated to be living with chronic HCV in 2024, compared with 129,000 in 2015. Around 81.5% of people diagnosed between 2015 and 2024 had initiated treatment, and 93.9% of patients with a recorded outcome achieved viral clearance. Remaining demand is increasingly concentrated among harder-to-reach patients, reinfections and people outside conventional specialist pathways.

Australia shows a similar post-expansion pattern. The country had an estimated 62,880 people living with chronic HCV in 2024, with approximately 5,240 initial treatments and 3,026 retreatments during the year. Reinfection represented a material source of repeat demand even as first-treatment volume declined. Egypt represents the opposite end of the pricing spectrum: a centralized program screened more than 60 million people and treated over 4.3 million, demonstrating the treatment volume possible through national financing and low-cost procurement.

China, India and the other high-burden Asian and African countries are likely to resemble the public-volume model more closely than the fragmented U.S. specialty model. Established HBV and HCV products must be affordable enough for national or regional programs, while new functional-cure and HDV therapies will initially enter narrower specialist populations with greater per-patient value.

 

Commercial Value Is Moving Toward Differentiated Treatment

The hepatitis therapeutics market is separating into mature volume products and smaller high-value categories. Established HBV antivirals generate long treatment duration but face generic and tender pressure. HCV DAAs remain commercially significant, but successful cure programs, generic competition and declining treatment starts constrain growth in mature markets. HDV drugs and HBV functional-cure candidates offer stronger premium potential because they address areas with limited treatment alternatives.

The ten-country concentration also changes commercial priorities. China and India are central to both global burden reduction and future pharmaceutical volume. Indonesia, Nigeria, Ethiopia, Bangladesh, Viet Nam and the Philippines are primarily HBV markets, where diagnosis and sustained access must expand before long-term drug demand reaches its potential. Pakistan and Russia offer comparatively larger HCV opportunities, where screening and rapid treatment initiation are the main revenue-conversion events.

Future demand will depend less on total prevalence than on how many patients are diagnosed, assessed, funded and linked to treatment. Manufacturers competing in mature HBV and HCV segments require efficient supply, tender capabilities and partnerships that connect testing with prescribing. Companies entering HDV or functional-cure categories require specialist education, biomarker-based patient selection, durable clinical evidence and payer proof that higher treatment costs can reduce long-term disease management.

 

Hepatitis Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 18.58 Billion
Revenue Forecast in 2032	USD 29.45 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Drug Class	Direct-Acting Antivirals; Nucleos(t)ide Analogues; Immune Modulators; Combination Therapies
By Disease Type	Hepatitis B; Hepatitis C; Others
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Rising Global Hepatitis Burden	Increasing prevalence of chronic HBV and HCV infections, liver-related complications, and treatment demand is supporting long-term market expansion.
Market Drivers – Expansion of Direct-Acting Antiviral Therapies	High cure rates from HCV direct-acting antivirals and continued demand for antiviral management are sustaining therapeutic adoption.
Market Drivers – Innovation in Functional Cure and Specialty Therapies	Development of HBV functional-cure candidates and emerging hepatitis D therapies is creating new premium treatment opportunities.
Market Drivers – Government Screening and Elimination Programs	National hepatitis elimination initiatives, expanded testing, and public treatment programs are increasing diagnosis-to-treatment conversion.
Customization Option	Available upon request